Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
- 31 January 2012
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 13 (1), 89-99
- https://doi.org/10.1016/s1470-2045(11)70286-8
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological studyThe Lancet, 2011
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide studyThe Lancet Oncology, 2010
- Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young WomenJNCI Journal of the National Cancer Institute, 2010
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenThe Lancet, 2009
- Health and Economic Implications of HPV Vaccination in the United StatesThe New England Journal of Medicine, 2008
- Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in FinlandBritish Journal of Cancer, 2007
- Highly Effective Detection of Human Papillomavirus 16 and 18 DNA by a Testing Algorithm Combining Broad-Spectrum and Type-Specific PCRJournal of Clinical Microbiology, 2006
- Incidence Trends of Adenocarcinoma of the Cervix in 13 European CountriesCancer Epidemiology, Biomarkers & Prevention, 2005
- A Longitudinal Study of Genital Human Papillomavirus Infection in a Cohort of Closely Followed Adolescent WomenThe Journal of Infectious Diseases, 2005
- TRENDS IN MORTALITY FROM CERVICAL CANCER IN THE NORDIC COUNTRIES: ASSOCIATION WITH ORGANISED SCREENING PROGRAMMESThe Lancet, 1987